Resection of TDLNs prior to tumour implantation and/or prior to anti-PD-1 treatment completely abolished or reduced efficacy respectively. CTLs in TDLNs express other targets (e.g. MTOR) which can be drugged to provide synergistic responses with anti-PD-1 therapy. This evidence concerns the gene MTOR and neoplasm.